# CGM - Reimagine Primary Care

Study · id `cardio:ct-nct04413578` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04413578](<https://clinicaltrials.gov/study/NCT04413578>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04413578

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

## Technical summary

Registry record NCT04413578. Randomized; no masking; primary purpose treatment. Start 2018-12-01 (actual); primary completion 2019-11-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 101 participants (enrolled count; ClinicalTrials.gov record NCT04413578, source copy `cardio:ctgov-nct04413578-2020-06-04`, retrieved 2026-10-26)
- Started: 2018-12-01 (actual) (ClinicalTrials.gov record NCT04413578, source copy `cardio:ctgov-nct04413578-2020-06-04`, retrieved 2026-10-26)
- Primary completion: 2019-11-28 (actual) (ClinicalTrials.gov record NCT04413578, source copy `cardio:ctgov-nct04413578-2020-06-04`, retrieved 2026-10-26)
- Completion: 2019-12-31 (actual) (ClinicalTrials.gov record NCT04413578, source copy `cardio:ctgov-nct04413578-2020-06-04`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04413578, source copy `cardio:ctgov-nct04413578-2020-06-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04413578-2020-06-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: CGM - Reimagine Primary Care
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): Dexcom G6
- Intervention (Device): Contour NextOne
- Lead sponsor: Intermountain Health Care, Inc.
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Intermountain Health Care, Inc. (`cardio:org-intermountain-health-care-inc`)

## Provenance

Content hash: 62b0a7ca0e50c2e41b4f1e5ee5fd38c2440677799d52dc5bf2848d9377e7c968
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
